Form 4 Filing for Celldex Therapeutics, Inc.

This filing reports a Form 4 for Celldex Therapeutics, Inc. (CLDX) concerning stock options granted to Director Cheryl Cohen. On June 25, 2026, Ms. Cohen was granted 26,000 non-qualified stock options with an exercise price of $34.09. These options, granted under the 2021 Omnibus Equity Incentive Plan, are exercisable until June 25, 2036. The transaction is categorized as an acquisition of securities. The filing was signed on June 29, 2026, by Sam Martin, acting as attorney-in-fact for Ms. Cohen. Ms. Cohen is a director at Celldex Therapeutics, Inc.